Shares of Optimi Health jumped 7.1% to $5.31 on September 24, bucking a weaker broader market, after the company announced it had completed production and quality release of a psilocybin capsule batch destined for both a Canadian clinical trial and commercial use in Australia. The move raises a pointed question: does this milestone mark a turning point for a micro-cap psychedelic firm, or is the market getting ahead of itself? Optimi Health Delivers Its Psilocybin Capsules for a Depression Trial and Australian Clinics — But Can $100K in Quarterly Revenue Justify the Hype?
Shares of Optimi Health surged 7.1% to $5.31 on a down day for the broader market after the company said it had finished manufacturing a batch of 5mg psilocybin capsules at its facility in Princeton, British Columbia. The announcement marks a concrete supply milestone — but for a company generating barely six figures in quarterly revenue, investors betting on this stock are wagering almost entirely on the future.
One Batch Feeds Two Markets, But Neither Is Large Yet. The capsules will supply a Health Canada-approved Phase 2 clinical trial for major depressive disorder enrolling up to 200 participants and commercial customers in Australia.
Patient dosing in the Canadian study isn't expected to wrap until the end of 2027. In Australia, updated regulations have broadened prescriber eligibility and treatment settings, reinforcing Australia's position as the world's leading commercial market for prescribed psilocybin. Yet Optimi disclosed neither the number of capsules in the batch nor new sales tied to it, leaving the revenue impact unquantified.
The Numbers Don't Yet Support the Narrative. Last quarter, Optimi reported just $101,275 in revenue.
Its second-quarter net loss widened to CA$1.59 million.
The market cap sits below US$34 million — tiny by pharma standards, but enormous relative to sales. The company also recently set up a US$100 million equity line — essentially a facility to sell new shares for cash — signaling it will likely need to dilute existing investors to fund operations.
A Clinical Pipeline Is Expanding Fast, But It's All Pre-Revenue. Beyond psilocybin, Optimi announced plans for a Health Canada-authorized Phase 3 trial of MDMA-assisted therapy for PTSD, targeting up to 100 veterans and frontline workers.
That trial isn't expected to begin until 2027.
Importantly, the psilocybin production release removes a supply hurdle for the Canadian study but is not authorization to market psilocybin in Canada.
Australia Is the Real Revenue Test. Patients with treatment-resistant depression have already been treated in Australia using Optimi's capsules under the Authorised Prescriber Scheme.
No serious adverse events have been reported among those patients as of December 2025. But treatments can cost around $30,000 per patient , limiting volume. The question isn't whether Optimi can make the product — it clearly can. The question is whether enough patients and jurisdictions will pay for it to turn a sub-micro-cap manufacturer into a real pharmaceutical business.